Form 4: Adverum Biotechnologies COO Reprices Stock Options Following Reverse Stock Split
Insider Transaction Report
Adverum Biotechnologies' Chief Operating Officer, Peter Soparkar, has had a significant portion of his stock options repriced to an exercise price of $10.14 per share, following a 1-for-10 reverse stock split.
Summary
- Peter Soparkar, Chief Operating Officer of Adverum Biotechnologies, Inc. (ADVM), reported the amendment of multiple stock options on June 17, 2025.
- The amendments involved the deemed cancellation of 'old' stock options and the simultaneous grant of 'replacement' options.
- The new exercise price for all replacement options is uniformly $10.14 per share.
- The total number of shares underlying these repriced options is 197,048.
- Original exercise prices for the cancelled options ranged significantly, from $12.90 to $157.50 per share, indicating that the previous options were substantially 'underwater' (had an exercise price higher than the current market price).
- The company effected a 1-for-10 reverse stock split on March 21, 2024, which adjusted the terms of existing stock options by multiplying exercise prices by ten and dividing the number of shares by ten.
- Some of the repriced options were fully vested at the time of amendment, while others have future vesting schedules extending to February 2028.
Sentiment
Score: 3
Explanation: The sentiment is generally negative due to the implications of option repricing, which typically occurs after significant stock price declines. While it aims to re-incentivize management, it signals past underperformance and potential shareholder dilution. The positive aspect of executive retention is outweighed by the underlying reasons for the repricing.
Positives
- The repricing of stock options can serve as a strong incentive for the Chief Operating Officer, Peter Soparkar, to remain with Adverum Biotechnologies and be motivated by the company's future stock performance.
- By making the options 'in-the-money' or closer to the current market price, the company aims to re-align executive incentives with shareholder value creation, especially after a significant stock price decline.
Negatives
- The necessity of repricing options from significantly higher exercise prices (up to $157.50) to $10.14 indicates a substantial decline in Adverum Biotechnologies' stock price, reflecting past underperformance.
- Option repricing can be viewed negatively by existing shareholders as it potentially dilutes their ownership percentage and transfers value to executives, especially if new options are granted at a lower price without a corresponding increase in company performance.
- The repricing may signal a lack of confidence in the company's ability to reach its previous stock price levels, which could concern investors.
Risks
- Shareholder dissatisfaction and potential negative perception due to the repricing of executive stock options, especially given the implied significant decline in stock value.
- Risk of further stock price volatility if the market reacts negatively to the implications of the option repricing.
- Potential for increased share dilution if the repriced options are exercised in the future.
Future Outlook
The document primarily details past and current compensation adjustments. It indicates future vesting schedules for some of the repriced options, with full vesting dates ranging from August 2025 to February 2028, contingent on the Reporting Person's continuous service.
Industry Context
Option repricing is a practice sometimes employed by biotechnology companies, particularly those in early or clinical stages, when their stock price has significantly declined, rendering existing employee stock options 'underwater' and ineffective as incentives. This action aims to re-motivate key executives by providing them with new options that have a realistic chance of becoming valuable, thereby aiding in retention and aligning future performance incentives.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Executive Compensation Adjustment | The company's board approved the amendment and repricing of stock options for Chief Operating Officer Peter Soparkar, effectively cancelling old 'underwater' options and granting new ones at a lower exercise price of $10.14 per share. This action follows a 1-for-10 reverse stock split. | 2025-06-17 | This decision aims to re-incentivize a key executive following a significant decline in stock price, which had rendered previous options ineffective. However, it raises questions about shareholder value protection and the board's oversight of executive compensation in the context of poor stock performance and potential dilution. |
Stakeholder Impact
- Shareholders: Potential negative impact due to implied past stock underperformance and the potential for future dilution from the newly repriced options. However, it could also be seen as a necessary step to retain and motivate key management.
- Employees (specifically Peter Soparkar): Positive impact as his stock options are now 'in-the-money' or closer to the current market price, restoring their incentive value and potentially improving retention.
Next Steps
- Continued vesting of certain repriced stock options for Peter Soparkar, contingent on his continuous service, with full vesting dates extending to February 2028.
Key Dates
| Date | Description |
|---|---|
| 2019-10-30 | Original grant date for 40,000 shares option (fully vested). |
| 2020-02-20 | Original grant date for 4,074 shares option (fully vested). |
| 2021-02-16 | Original grant date for 13,999 shares option (fully vested). |
| 2021-08-06 | Original grant date for 15,999 shares option (fully vested). |
| 2022-02-18 | Vesting start date for 25,500 shares option (25% vested on first anniversary, then 1/48 monthly). |
| 2022-03-08 | Original grant date for 25,500 and 13,000 shares options. |
| 2022-09-14 | Original grant date for 23,092 shares option (fully vested) and 16,384 shares option. |
| 2023-08-16 | Vesting start date for 13,000 shares option (equal monthly installments over two years). |
| 2024-02-12 | Original grant date and vesting start date for 45,000 shares option (25% vested on first anniversary, then 1/48 monthly). |
| 2024-03-21 | Effective date of 1-for-10 reverse stock split. |
| 2025-06-17 | Date of earliest transaction (option amendment). |
| 2025-06-20 | Signature date of the SEC filing. |
| 2025-08-16 | Expected full vesting date for 13,000 shares option. |
| 2025-09-14 | Expected full vesting date for 16,384 shares option. |
| 2026-02-18 | Expected full vesting date for 25,500 shares option. |
| 2028-02-12 | Expected full vesting date for 45,000 shares option. |
| 2029-10-29 | Expiration date for 40,000 shares option. |
| 2030-02-19 | Expiration date for 4,074 shares option. |
| 2031-02-15 | Expiration date for 13,999 shares option. |
| 2031-08-05 | Expiration date for 15,999 shares option. |
| 2032-03-07 | Expiration date for 25,500 and 13,000 shares options. |
| 2032-09-13 | Expiration date for 23,092 and 16,384 shares options. |
| 2034-02-11 | Expiration date for 45,000 shares option. |
Keywords
Adverum Biotechnologies, ADVM, SEC Form 4, stock options, option repricing, executive compensation, Peter Soparkar, Chief Operating Officer, reverse stock split, insider transaction, corporate governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.